Group 1: Company Overview and Market Position - Jiangsu Senxuan Pharmaceutical Co., Ltd. has a securities code of 830946 and is known as Senxuan Pharmaceutical [1] - The company is focusing on a dual market strategy, targeting both domestic and international markets with a goal of 50% market share in each [6] Group 2: Product Development and Market Trends - The company has completed the construction phase of its 40 tons of Lopinavir and 60 tons of Rufinamide raw material projects, with market approval expected by 2025 [6] - The market for Lopinavir is competitive, especially after the COVID-19 pandemic, with many new entrants increasing competition [6] - The company plans to launch 1 to 2 new raw material drug varieties each year, focusing on high-value and low-investment products in the antiviral and antitumor fields [8] Group 3: Pricing and Procurement Strategies - The company does not directly participate in centralized procurement but is affected by it, particularly for its Fluorouracil raw material, which has seen price declines due to procurement policies [7] - The company aims to stabilize its performance by enhancing product quality and expanding registration breadth in response to price pressures [7] Group 4: International Market and Registration - The company has successfully registered six raw materials in Europe, including Fluorouracil and Rufinamide, with stable commercial orders expected to grow [8] - The overseas market strategy focuses on high-end products, leveraging quality and regulatory support to compete against lower-priced Indian products [9] Group 5: Financial Performance and Profit Margins - The gross margin for raw materials is lower in overseas markets compared to domestic markets due to a mix of high-end and low-end sales [13] - The domestic market benefits from a more stable competitive environment, leading to higher gross margins [13] Group 6: Future Development Focus - The company will continue to focus on four main business areas: refining raw materials, expanding new materials, specializing in intermediates, and developing innovative and generic drugs [14] - Increased investment in R&D is planned to maintain stable growth and enhance competitive advantages [14]

Group 1: Company Overview and Market Position - Jiangsu Senxuan Pharmaceutical Co., Ltd. has a securities code of 830946 and is publicly listed [1] - The company is focusing on a dual market strategy, targeting both domestic and international markets with a goal of 50% market share in each [6] Group 2: Product Development and Market Trends - The company has completed the construction phase of its 40 tons of Lopinavir and 60 tons of Rufinamide raw material projects, with market approval expected by 2025 [6] - The company plans to launch 1 to 2 new raw material drug varieties each year, focusing on high-value and low-investment products in the antiviral and anti-tumor fields [8] Group 3: Competitive Advantages and Challenges - Senxuan's core competitive advantage lies in its comprehensive quality system and regulatory registration, which helps it navigate the competitive landscape of raw materials [6] - The company faces increased competition in the raw material market, particularly for Lopinavir, due to new entrants following the COVID-19 pandemic [6] Group 4: Pricing and Market Strategy - The company does not directly participate in centralized procurement but is affected by pricing pressures from downstream formulation products [7] - The company anticipates a downward trend in raw material prices, but aims to stabilize performance by enhancing product quality and expanding market share [7] Group 5: International Market Presence - Senxuan has successfully registered six raw materials in Europe, including Fluorouracil and Rufinamide, with stable commercial orders expected to grow [8] - The company positions itself in high-end markets, leveraging product quality and efficient registration support to compete against lower-priced Indian products [9] Group 6: Financial Performance and Profit Margins - The gross margin for raw materials is lower in overseas markets compared to domestic markets due to a mixed sales approach and competition [13] - The company aims to optimize existing products and increase R&D investment to maintain stable growth in performance [14]

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-055 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 28 日 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼 会议室 3.会议召开方式：以现场加通讯方式召开 4.发出董事会会议通知的时间和方式：2024 年 10 月 18 日以书面、邮件等方 式发出 5.会议主持人：吴玉祥 6.会议列席人员：公司监事、高级管理人员 江苏森萱医药股份有限公司 江苏森萱医药股份有限公司 1.议案内容： 具体内容详见公司于同日在北京证券交易所信息披露平台（www.bse.cn）披 露的《2024 年第三季度报告》（公告编号：2024-057）。 2.议案表决结果：同意 7 票；反对 0 票；弃权 0 票。 本议案已经公司第四届董事会审计委员会第六次会议审议通过。 7.召开情况合法、 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-056 江苏森萱医药股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 28 日 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼会议 室 3.会议召开方式：以现场加通讯方式召开 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 监事封乃军因出差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2024 年第三季度报告>的议案》议案 1.议案内容： 江苏森萱医药股份有限公司 具体内容详见公司于同日在北京证券交易所信息披露平台（www.bse.cn）披 露的《2024 年第三季度报告》（公告编号：2024-057）。 2.议案表决结果：同意 3 票；反对 0 ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-09- | | | | | 国泰君安证券股份有 | 方正证券股份有限公 | | 02 | 830946 | 森萱医药 | 4.49 | 340000 | 限公司浙江宁波广福 | 司杭州平澜路证券营 | | | | | | | 街营业部 | 业部 | | 2024-09- | | | | | 国泰君安证券股份有 | 方正证券股份有限公 | | 02 | 832491 | 奥迪威 | 8.75 | 230000 | 限公司浙江宁波广福 | 司杭州平澜路证券营 | | | | | | | 街营业部 | 业部 | | 2024-09- | | | | | 中信建投证券股份有 | 中信建投证券股份有 | | 02 | 831689 | 克莱特 | 8.81 | 720000 | 限公司济南经四路证 | 限公司北京海淀分公 | | | | | | | 券营业部 | 司 | | 2024-09- | | | | | 财信证券股 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-053 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 8 月 26 日 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼 会议室 3.会议召开方式：以现场加通讯方式召开 4.发出董事会会议通知的时间和方式：2024 年 8 月 16 日以书面、邮件等方 式发出 5.会议主持人：吴玉祥 江苏森萱医药股份有限公司 第四届董事会第五次会议决议公告 6.会议列席人员：公司监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事袁拥军、沈小燕、任勇、曹翠萍因出差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2024 年半年度报告>及<2024 年半年度报 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥272,084,703.46, a decrease of 14.33% compared to ¥317,588,772.54 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was ¥69,680,607.02, down 9.07% from ¥76,632,214.85 year-on-year[14]. - The gross profit margin improved to 43.97%, compared to 42.98% in the previous year[14]. - The company reported a revenue of 272.08 million yuan, a decrease of 14.33% year-over-year[21]. - Net profit attributable to shareholders was 69.68 million yuan, down 9.07% compared to the previous year[21]. - The company's net profit for the first half of 2024 was 70,693,561.07, a decrease of 12.3% compared to 80,516,417.50 in the same period of 2023[78]. - The total comprehensive income for the first half of 2024 was 70,693,561.07, compared to 80,516,417.50 in the same period of 2023, reflecting overall reduced profitability[78]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,314,278,061.45, a slight decrease of 0.98% from ¥1,327,313,296.09 at the end of the previous year[15]. - Total liabilities decreased by 12.44% to ¥103,094,419.79 from ¥117,735,441.12 year-on-year[15]. - The total assets growth rate was -0.98%, with total assets showing a decline of 3.32% year-over-year[17]. - The company's total equity increased slightly to CNY 1,211,183,641.66 from CNY 1,209,577,854.97, showing a growth of about 0.1%[72]. - The total equity attributable to the parent company at the end of the period is CNY 1,209,577,854.97[85]. Cash Flow - The net cash flow from operating activities was ¥60,210,377.31, an increase of 3.81% compared to ¥57,999,349.25 in the same period last year[16]. - Cash flow from operating activities was 60.21 million yuan, reflecting a decrease of 3.81% year-over-year[21]. - The net cash flow from investing activities significantly improved to ¥40,428,863.02, a 157.11% increase from a negative ¥70,787,210.78 in the previous period[32]. - The company reported a net cash increase of CNY 28,204,955.35, contrasting with a net decrease of CNY 110,582,134.55 in the first half of 2023[82]. Inventory and Receivables - The company’s inventory turnover rate was 1.05, compared to 1.20 in the same period last year[16]. - The company’s inventory decreased slightly by 1.99% to 143.08 million yuan, accounting for 10.89% of total assets[23]. - Accounts receivable decreased by 5.88 million yuan, down 37.11%, mainly due to an increase in bill financing from state-owned banks[25]. - The accounts receivable at the end of the period amounted to ¥63,899,921.02, an increase from ¥36,039,916.99 at the beginning of the period, representing a growth of 77.5%[165]. Environmental Compliance - The company passed the FDA inspection in May 2024, indicating compliance with U.S. regulatory standards[3]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[35]. - The company has obtained various environmental permits, with the latest expiring in 2029[36]. - The company has implemented a wastewater treatment process that combines industrial and domestic wastewater before discharging it to the park's wastewater treatment plant[40]. - The company conducts annual monitoring of key exhaust gas factors including dichloromethane, methanol, hydrochloric acid, ammonia, and odor concentration[44]. Risk Factors - The company faces tax policy risks as some subsidiaries currently enjoy tax incentives for high-tech enterprises, which may be revoked if conditions are not met, potentially impacting operations[53]. - The company is exposed to foreign exchange risks due to fluctuations in the RMB against foreign currencies, which could lead to exchange losses as it expands overseas sales[53]. - Raw material price volatility poses a risk to profitability, with the company implementing a warning system to manage significant price changes[53]. - The company is at risk of intensified market competition from both domestic and international players in the pharmaceutical and chemical sectors, prompting increased R&D investment and cost optimization[53]. Shareholder Information - The total number of ordinary shares at the end of the reporting period was 426,918,340, with 99.9517% being unrestricted shares[64]. - The largest shareholder, Jinghua Pharmaceutical Group Co., Ltd., holds 308,724,340 shares, representing 72.31% of total shares[65]. - The company declared a cash dividend of 1.6 RMB per 10 shares, totaling 68,306,934.40 RMB based on 426,918,340 shares[95]. Accounting Policies - The company has not made any changes to accounting policies or estimates compared to the previous financial statements[94]. - The financial statements are prepared based on the going concern assumption, with sufficient operating funds for at least 12 months from the approval date[99]. - The company adheres to the accounting standards and ensures that the financial statements reflect its financial position, operating results, and cash flows accurately[101].

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-054 江苏森萱医药股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 监事封乃军、童军因出差以通讯方式参与表决。 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼会议 室 3.会议召开方式：以现场加通讯方式召开 4.发出监事会会议通知的时间和方式：2024 年 8 月 16 日 以书面、邮件等方式发 出 5.会议主持人：秦建 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 （一）会议召开情况 1.会议召开时间：2024 年 8 月 26 日 （二）审议通过《关于审议<2024 年 1-6 月募集资金存放与使用情况的专项报告> 二、议案审议情况 （一）审议通过《关于审议<2024 年半年度报 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-052 江苏森萱医药股份有限公司 2024 年 1-6 月募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 （一）2020 年公开发行募集资金基本情况 经中国证券监督管理委员会《关于核准江苏森萱医药股份有限公司向不特定 合格投资者公开发行股票的批复》（证监许可[2020]1302 号），核准公司向不特 定合格投资者公开发行不超过 9,000 万股新股，公司第三届董事会第二次会议在 股东大会的授权范围内确定最终发行股份为 6,000 万股，经询价后和主办券商开 源证券股份有限公司确定本次发行价格人民币 5.40 元/股，募集资金总额人民币 32,400.00 万元，公司募集资金扣除需支付的承销、保荐费用 2,106.00 万元后 的 30,294.00 万元已于 2020 年 7 月 16 日全部存入公司开立的江苏张家港农村商 业银行股份有限公司南通分行的 8 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2024-049 江苏森萱医药股份有限公司股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 75,000 股，占公司总股本 0.0176%，可交易 时间为 2024 年 8 月 23 日。 二、本次股票解除限售的明细情况及原因 单位：股 | | | 是否为控 | | | | 本次解 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 股股东、 | 董事、监 | | 本次解除 | 除限售 | 尚未解除 | | | 序号 | 股东姓名 | 实际控制 | 事、高级 | 本次解限 | 限售登记 | 股数占 | 限售的股 | | | | 或名称 | | 管理人员 | 售原因 | | 公司总 | | | | | | 人或其一 | | | 股票数量 | | 票数量 | | | | | 致行动人 | 任职情况 ...